Pretreatment with a long-acting GnRH agonist for frozen-thawed embryo transfer cycles: how to improve live birth?

Table 1 Characteristics of patients

Characteristics	GnRHa FET (n = 630)	HRT without GnRHa (n = 1141)	P
Age	32.1 ± 5.2	32.4 ± 5.3	0.306
Duration of infertility	4.8 ± 3.6	5.1 ± 3.9	0.127
Type of infertility			0.108
Primary	310/630 (49.2)	516/1141 (45.2)
Secondary	320/630 (50.8)	516/1141 (54.8)
Number of pregnancies	1.2 ± 1.4	1.2 ± 1.5	0.245
PCOS(%)	111 (17.6)	238 (20.9)	0.101
DOR(%)	86 (13.7)	183 (16.0)	0.180
Scarred uterus(%)	102 (16.2)	158 (13.8)	0.182
Endometriosis(%)	23 (3.7)	36 (3.2)	0.578
Number of transferred embryos	1.7 ± 0.4	1.7 ± 0.4	0.890
Grade of transferred embryos^a			0.472
Cleavage I	160 (22.7)	277 (23.9)
Cleavage II	331 (46.9)	548 (47.4)
Blastocyst	215 (30.5)	332 (28.7)

GnRHa Gonadotropin-releasing hormone agonist, HRT Hormone replacement treatment, PCOS Polycystic ovary syndrome, DOR Decreased ovarian reserve
^aIf transferred embryo including at least one grade I cleavage embryo, one or two grade II cleavage embryo, and one or two blastocysts were classified as Cleavage I, Cleavage II, and blastocyst respectively

ISSN: 1757-2215